Pear Therapeutics (PEAR) Tops Q4 EPS by 54c

Pear Therapeutics (NASDAQ: PEAR) reported Q4 EPS of $0.13, $0.54 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.32 million versus the consensus estimate of $1.47 million.

GUIDANCE:

Pear Therapeutics sees FY2022 revenue of $22 million.

For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Full Truck Alliance (YMM) Tops Q2 EPS by 10c; beats on guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance